The US Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax Covid-19 vaccine for use in people 12 and up. Doses could be available by the end of next week.

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

The FDA has authorized Novavax's new formula, adding to a repertoire of revamped COVID vaccines. Here's what to know about cost and more. Jessica Rendall Wellness Reporter Jessica is a writer on ...

US Clears Updated COVID Shots From Novavax, Adding a 3rd Fall Vaccine Option U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already ...

Novavax has an Earnings ESP of -70.16% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong ...

(Reuters) -Novavax on Thursday trimmed its annual revenue forecast again and said it would pare back its presence in Europe through the rest of the year, ahead of handing over the rights to sell ...

Novavax’s vaccine is based on protein technology, which takes longer to manufacture than mRNA vaccines like those made by Pfizer and BioNTech and Moderna. Protein-based vaccines work by getting ...

As of 11:21 AM EDT. Market Open. Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects ...